Neuronetics, INC Schedule 13D activist filings

Neuronetics, Inc. and major shareholder Jorey Chernett have established a framework for board alignment, including Chernett's opportunity to recommend a new board member.

Jorey Chernett has filed an amendment to Schedule 13D, reporting increased beneficial ownership of Neuronetics, Inc. common stock to 15.17%.

Jorey Chernett, a significant shareholder in Neuronetics, Inc., has formally requested a comprehensive review of strategic alternatives, including a potential sale of the company's TMS business.

Jorey Chernett has filed a Schedule 13D, disclosing a 14.12% beneficial ownership in Neuronetics, Inc., citing the shares as an undervalued investment opportunity.

Madryn Asset Management and its affiliates updated their Schedule 13D filing for Neuronetics, Inc., disclosing a 30.3% beneficial ownership and new terms for registration rights and voting agreements.

Madryn Asset Management and its affiliates have reduced their aggregate beneficial ownership in Neuronetics, Inc. to 31.4% after selling over 3.5 million shares.